Several other research firms have also recently weighed in on GRFS. Berenberg Bank reissued a buy rating on shares of GRIFOLS S A/S in a research report on Wednesday, June 10th. HSBC upgraded GRIFOLS S A/S from a reduce rating to a hold rating in a report on Tuesday, June 9th. Barclays reiterated an overweight rating on shares of GRIFOLS S A/S in a report on Monday, June 1st. Morgan Stanley restated an overweight rating on shares of GRIFOLS S A/S in a report on Tuesday, June 23rd. Finally, Citigroup lowered GRIFOLS S A/S from a neutral rating to a sell rating in a research report on Tuesday, June 9th. Two equities research analysts have rated the stock with a sell rating, five have assigned a hold rating and six have issued a buy rating to the stock. The company has an average rating of Hold and an average target price of $24.00.
Shares of GRFS opened at $19.22 on Friday. GRIFOLS S A/S has a 1 year low of $13.40 and a 1 year high of $25.73. The company has a market cap of $12.76 billion, a price-to-earnings ratio of 17.16, a price-to-earnings-growth ratio of 0.98 and a beta of 0.82. The company has a debt-to-equity ratio of 0.95, a quick ratio of 0.90 and a current ratio of 2.75. The firm has a fifty day moving average of $19.19 and a 200-day moving average of $21.07.
Institutional investors have recently bought and sold shares of the company. AKO Capital LLP increased its holdings in GRIFOLS S A/S by 6.7% during the 1st quarter. AKO Capital LLP now owns 13,241,833 shares of the biotechnology company’s stock valued at $266,691,000 after purchasing an additional 835,287 shares during the period. TPG Group Holdings SBS Advisors Inc. boosted its position in shares of GRIFOLS S A/S by 134.8% in the 1st quarter. TPG Group Holdings SBS Advisors Inc. now owns 4,591,797 shares of the biotechnology company’s stock worth $92,479,000 after purchasing an additional 2,636,372 shares in the last quarter. Janus Henderson Group PLC raised its holdings in GRIFOLS S A/S by 70.5% in the 1st quarter. Janus Henderson Group PLC now owns 4,023,224 shares of the biotechnology company’s stock worth $80,587,000 after acquiring an additional 1,662,872 shares during the last quarter. Baillie Gifford & Co. purchased a new position in GRIFOLS S A/S in the 1st quarter worth approximately $63,958,000. Finally, UBS Asset Management Americas Inc. raised its holdings in GRIFOLS S A/S by 21.4% in the 4th quarter. UBS Asset Management Americas Inc. now owns 3,017,131 shares of the biotechnology company’s stock worth $70,269,000 after acquiring an additional 531,849 shares during the last quarter. 17.80% of the stock is owned by hedge funds and other institutional investors.
GRIFOLS S A/S Company Profile
Grifols, SA, a specialty pharmaceutical company, develops, manufactures, and distributes a range of biological medicines on plasma derived proteins worldwide. The company operates through five segments: Bioscience, Diagnostic, Hospital, Bio Supplies, and Others. The Bioscience segment manufactures plasma derivatives for therapeutic use; and sells and distributes end products.
Recommended Story: Cost of Equity For A Business, Investors
Receive News & Ratings for GRIFOLS S A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GRIFOLS S A/S and related companies with MarketBeat.com's FREE daily email newsletter.